24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Cancer
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:18
Bybit breach: How hackers stole $1.5 billion without breaking blockchain security
15:07
Adi Dangot Zukovsky joins Ibex Investors as partner following fund’s leadership shift
14:54
‘It was through their lies that they became multimillionaires’: Charlie Javice fraud trial opens
14:31
AI won’t replace developers—but it will change who gets hired
More stories
Buzz
Most popular
Daily
Weekly
1
Insight Partners hit by cyber attack with possible data leaks
2
CyberArk’s surge, Wiz and Cato prepare for IPOs: Israeli cyber firms ready for the next big move
3
Riskified cuts staff as struggles continue
4
How Intel ruined an Israeli startup it bought for $2B—and lost the AI race
5
Adi Dangot Zukovsky joins Ibex Investors as partner following fund’s leadership shift
More news
Cancer
8 stories about Cancer
Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company
10.12.17
|
Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17
|
Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor
VBL Therapeutics Aims to Raise $18.75 Million in Public Offering
20.11.17
|
Lilach Baumer
The cancer treatment company announced an offering of 2.5 million shares last week
Pontifax Leads $9.5 Funding Round for Biopharmaceutical Company ArQule
19.11.17
|
CTech
Nasdaq-listed ArQule develops treatments for cancer and rare diseases
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17
|
Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
Cancer Treatment Company Negotiating $20-25 Million Capital Injection
29.10.17
|
Lilach Baumer
The potential investors condition the investment on delisting BioCanCell from the Tel Aviv Stock Exchange
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17
|
Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
Kite Pharma Sale Triggers Scientist Quarrel
02.10.17
|
Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
Previous Articles